Asset Planning Inc Purchases New Shares in DexCom, Inc. (NASDAQ:DXCM)

Asset Planning Inc purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,300 shares of the medical device company’s stock, valued at approximately $101,000.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at $25,000. Riverview Trust Co lifted its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of DexCom during the 4th quarter valued at $38,000. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom during the 3rd quarter valued at $57,000. Finally, Covestor Ltd lifted its position in shares of DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Up 0.3 %

Shares of NASDAQ:DXCM opened at $84.09 on Friday. The business’s 50 day simple moving average is $82.11 and its two-hundred day simple moving average is $75.19. The firm has a market cap of $32.85 billion, a P/E ratio of 50.35, a PEG ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. As a group, research analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Activity

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock worth $3,628,069 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on DXCM shares. Wells Fargo & Company upped their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Raymond James cut their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Oppenheimer cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.